Supporting this are observation that high Cyclin D1 expression levels correlate with long-term prognosis in ILC [49], and the finding that the CDK4/6 inhibitor abemaciclib induces upregulation of Cyclin D1 in luminal-type ER+ and lobular-type breast cancer cell lines [50]. Here, CCND1 is linked to breast carcinoma.